razoxane has been researched along with Myelodysplastic Syndromes in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chauvenet, A; Constine, LS; De Alarcon, PA; Friedman, D; London, WB; Mendenhall, NP; Schwartz, CL; Sposto, R; Tebbi, CK; Villaluna, D | 1 |
| Lipshultz, SE; Lipsitz, SR; Orav, EJ | 1 |
1 trial(s) available for razoxane and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Chelating Agents; Cohort Studies; Enzyme Inhibitors; Female; Follow-Up Studies; Heart Diseases; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid; Lung Diseases; Male; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Osteosarcoma; Razoxane; Risk Assessment; Risk Factors; Thyroid Neoplasms; Time Factors; Topoisomerase II Inhibitors | 2007 |
1 other study(ies) available for razoxane and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neoplasms, Second Primary; Randomized Controlled Trials as Topic; Razoxane; Risk Assessment; Scientific Misconduct; Sensitivity and Specificity; Survival Rate | 2007 |